Agenus reported $15.05M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Celldex Therapeutics USD -82.25M 1.63M Sep/2026
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.13B 166M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 6.47B 1B Sep/2026
Jiangsu Hengrui CNY 2.85B 1.17B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Merck EUR 660M 437M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Northwest Biotherapeutics USD -10.9M 3.42M Mar/2026
Novartis USD 5.14B 392M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 18.02M 5.94M Sep/2026